Details for Patent: 8,669,273
Which drugs does patent 8,669,273 protect, and when does it expire?
Patent 8,669,273 protects NERLYNX and is included in one NDA.
This patent has thirty-nine patent family members in twenty-five countries.
Summary for Patent: 8,669,273
| Title: | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | A combination of a 4-anilino-3-cyanoquinoline compound (e.g. HKI-272, SKI-606, EKB-569) and a capecitabine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Charles Michael Zacharchuk, Susan Elizabeth Quinn, Kenneth Kuan-Yuen Wang, Florence Marie Helene Binlich | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Wyeth LLC | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US12/534,895 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Delivery; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 8,669,273: Neratinib and Capecitabine Patent Scope, Expiration, and Patent LandscapeUS Patent 8,669,273 protects specific combination-treatment methods using neratinib and capecitabine for ErbB-2-positive metastatic or locally advanced breast cancer. Its strongest commercial coverage is the regimen in claim 23: daily oral neratinib during a 21-day cycle combined with capecitabine on days 1 through 14. The patent does not broadly cover neratinib, capecitabine, or all breast-cancer treatment. It covers a defined combination, patient population, dosing framework, and asserted synergistic effect. The patent is assigned to Wyeth, now within Pfizer’s corporate patent history. Puma Biotechnology obtained rights to develop and commercialize neratinib from Pfizer. The patent’s projected ordinary expiration is in 2029, subject to the patent’s recorded term adjustment and any applicable terminal disclaimer. It is not the principal composition-of-matter patent for neratinib. What does US Patent 8,669,273 cover?The patent covers methods that satisfy all of the following core limitations:
The independent claims are method-of-treatment claims, not product claims. A party would generally need to practice the claimed combination regimen to create infringement risk. Selling neratinib alone, selling capecitabine alone, or treating a cancer that does not satisfy the ErbB-2-positive limitation would not, by itself, practice the central claimed method. How do claims 1 and 23 differ?Claim 1 is broad in therapeutic concept but contains several important limitations. Claim 23 is narrower in dosing and scheduling but may be commercially more relevant because it maps more closely to a recognizable treatment protocol.
Claim 23 is not merely a claim to co-administration. It requires the particular 21-day cycle and the day 1-to-day 14 capecitabine schedule. A generic manufacturer or clinical operator would need to assess whether its proposed labeling, instructions, or foreseeable use would induce practice of those limitations. What is the scope of the synergy limitation?The phrase “wherein neratinib and capecitabine act synergistically” is a material limitation in claims 1 and 23. It narrows the claims beyond simple additive combination therapy. The patent’s technical theory is that inhibition of ErbB-family signaling by neratinib can enhance the antitumor activity of capecitabine or its active metabolite, 5-fluorouracil. The asserted synergy is relevant to patentability because it supports an argument that the claimed combination produced an unexpected therapeutic result. The limitation also creates enforcement and validity issues:
The synergy limitation is therefore both a scope restriction and a potential litigation pressure point. It may make the claims harder to invalidate on anticipation, while also making infringement proof more demanding. What formulations and dosage forms are protected?US 8,669,273 is not principally a formulation patent. It does not claim a particular tablet composition, capsule architecture, excipient system, coating, particle size, salt, polymorph, or fixed-dose combination product. The patent protects administration of the active agents. Relevant covered variables include:
A separate product could therefore raise different patent questions for:
A product or formulation patent would need to be analyzed separately from the treatment-method claims in US 8,669,273. When does US Patent 8,669,273 expire?The patent was issued on March 11, 2014. Its ordinary projected patent-term expiration is approximately January 2029, based on the underlying US/PCT filing history. The precise terminal date must be taken from the USPTO patent record because patent-term adjustment can change the expiration date.
The patent’s expiration is not the same as the expiration of every neratinib patent. Neratinib may be protected by composition, formulation, manufacturing, crystalline-form, or other method-of-use patents with different dates. What is the Orange Book status of US 8,669,273?US 8,669,273 should not be treated as an automatic Orange Book barrier merely because it concerns neratinib. Orange Book listing is tied to patents that claim the approved drug substance, drug product, or an FDA-approved method of use. Nerlynx is approved for extended adjuvant treatment of early-stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy. The patented method in US 8,669,273 concerns neratinib plus capecitabine for metastatic or locally advanced ErbB-2-positive breast cancer. That combination is not the principal FDA-approved Nerlynx indication. Accordingly:
What FDA exclusivity protects neratinib?Neratinib received FDA approval for Nerlynx in July 2017. The approved use was extended adjuvant treatment of early-stage HER2-positive breast cancer after trastuzumab-based adjuvant therapy, not the neratinib-capecitabine metastatic regimen claimed in US 8,669,273.[2] FDA regulatory exclusivity and patent exclusivity operate separately:
The approval of Nerlynx does not establish FDA approval of the patented neratinib-capecitabine regimen. A generic applicant could seek approval for a different indication or use a section viii statement to carve out protected methods if the statutory and labeling requirements are met. Are Paragraph IV challenges likely for this patent?A Paragraph IV challenge is relevant only if US 8,669,273 is listed in the Orange Book for the relevant reference-listed drug. If it is not listed, an ANDA applicant would not ordinarily certify against it through the standard Orange Book mechanism. Potential challenge theories include: Lack of anticipationA challenger would search for earlier disclosures of:
A prior-art reference would generally need to disclose all elements of the relevant claim, either expressly or inherently. ObviousnessThe strongest obviousness theory would combine known neratinib activity in HER2-positive disease with known capecitabine use in metastatic breast cancer. The patent holder would respond that the particular combination, dosing, schedule, and synergistic effect were not predictable. IndefinitenessThe “synergistically” limitation may be challenged if the patent fails to identify an objective standard for determining synergy. The strength of this challenge depends on the specification, prosecution history, expert evidence, and claim construction. Enablement and written descriptionClaims 1 and 23 cover a range of disease states, doses, sequencing arrangements, and treatment durations. A challenger could argue that the disclosure does not enable the full breadth of those combinations. No publicly established Paragraph IV litigation against US 8,669,273 is identified here. Generic litigation concerning other neratinib patents would not establish a challenge to this patent. Which companies are relevant to the patent landscape?The principal commercial parties are:
Capecitabine is a mature small-molecule product with broad generic availability. It is not the principal commercial barrier in this combination. The commercial protection is concentrated in neratinib access, approved labeling, clinical positioning, and the remaining patent estate. How strong is the patent estate for the neratinib-capecitabine combination?US 8,669,273 has moderate strategic value but limited standalone breadth. Strengths
Weaknesses
The strongest practical value is claim 23 when a competitor’s clinical protocol or labeling mirrors the claimed cycle. The weakest position is against a product that does not promote the combination and whose foreseeable use does not follow the claimed regimen. What generic launch risks exist?A generic neratinib launch would create several distinct risk categories:
A “skinny label” strategy could reduce risk if protected combination use is omitted from the proposed labeling and the remaining label does not encourage that use. It would not eliminate liability if the patent holder proves that the manufacturer actively encouraged the patented combination through marketing, instructions, or other conduct. What patent litigation and settlement issues matter?The key litigation questions are:
A settlement involving a different neratinib patent does not necessarily resolve rights under US 8,669,273. Each patent must be included expressly or addressed through a sufficiently broad license. What geographic coverage does the patent provide?US 8,669,273 provides rights only in the United States. Parallel patent families may exist in Europe, Canada, Japan, Australia, and other jurisdictions, but foreign rights depend on national grants, claim amendments, opposition proceedings, and local expiration dates. A US patent does not block:
For global licensing or launch planning, the US patent must be mapped against each foreign family member and local regulatory indication. Key Takeaways
FAQsDoes US Patent 8,669,273 cover neratinib monotherapy?No. The independent claims require administration of both neratinib and capecitabine. Does the patent cover trastuzumab and capecitabine combinations?No. The claims identify neratinib and capecitabine. Trastuzumab-based regimens fall outside the literal combination claimed. Can a competitor avoid claim 23 by changing the capecitabine schedule?Potentially. A materially different schedule may avoid literal infringement, although the doctrine of equivalents and other patent claims would require separate analysis. Is capecitabine’s generic availability enough to defeat the patent?No. Generic availability of capecitabine does not invalidate a method patent covering its combination with neratinib. Is this patent a biosimilar barrier?No. Neratinib and capecitabine are small molecules. The relevant regulatory pathway is an ANDA or other small-molecule pathway, not a biosimilar application under the Biologics Price Competition and Innovation Act. References
More… ↓ |
Drugs Protected by US Patent 8,669,273
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 8,669,273 | ⤷ Start Trial | USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,669,273
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2009279771 | ⤷ Start Trial | |||
| Brazil | PI0916694 | ⤷ Start Trial | |||
| Canada | 2730715 | ⤷ Start Trial | |||
| China | 102202667 | ⤷ Start Trial | |||
| China | 105147713 | ⤷ Start Trial | |||
| China | 105963313 | ⤷ Start Trial | |||
| China | 109464445 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
